Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | May 30, 2024 | June 03, 2024 |
| PAREXEL INTERNATIONAL CORPPRXL · Entity 172709 | Corp. VP & Interim CFO | December 07, 2016 | December 09, 2016 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | January 02, 2026 | January 06, 2026 |
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2034-05-29 | Direct | 25,000 |
Reported balance
After 2024-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025 |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025
PAREXEL INTERNATIONAL CORP
Report date December 07, 2016 · Filed December 09, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,468 |
Reported balance
After 2016-12-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-12-07 · Grant · Acquired 2,348 · Balance 8,468 F1: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan.
PTC THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,666 |
Ending reported balance
After 2026-01-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 10,666 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Row 2 · 2026-01-05 · Exercise / conversion · Acquired 734 · Balance 11,400 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Row 3 · 2026-01-05 · Sale · Disposed 734 · Balance 10,666 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01 | Direct | 3,475 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F3: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.54 · Expires 2035-01-02 | Direct | 0 |
Reported balance
After 2026-01-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-05 · Exercise / conversion · Disposed 734 · Balance 0 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F4: Currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.
F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.
F3: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
F4: Currently exercisable.
Whitehawk Therapeutics, Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12 | Direct | 38,040 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.06 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 37,527 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-15 · Disposition to issuer · Disposed 73,428 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.04 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-15 · Disposition to issuer · Disposed 11,777 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-15 · Disposition to issuer · Disposed 17,666 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-15 · Disposition to issuer · Disposed 80,971 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-15 · Disposition to issuer · Disposed 66,950 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 21:26 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 38,040 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001680329-26-000005 · form4-06152026_090628.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,040 Underlying: Common Stock · 38,040 shares Expires 2036-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 734 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001680329-26-000002 · form4-01062026_050117.xml · derivative · entry 5 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 734 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F4 · derivative.exercise_date: Currently exercisable. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 734 | $76.00 | $55,784.00 |
DisclosureSEC source: 0001680329-26-000002 · form4-01062026_050117.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,666 F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 734 | $46.54 | $34,160.36 |
DisclosureSEC source: 0001680329-26-000002 · form4-01062026_050117.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 3,475 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001680329-26-000002 · form4-01062026_050117.xml · derivative · entry 4 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,475 Underlying: Common Stock · 3,475 shares Expires 2036-01-01 F3 · derivative.exercise_date: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001680329-26-000002 · form4-01062026_050117.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,666 F1 · shares: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 733 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001680329-25-000014 · form4-12052025_051201.xml · derivative · entry 3 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 734 Underlying: Common Stock · 733 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 733 | $78.62 | $57,628.46 |
DisclosureSEC source: 0001680329-25-000014 · form4-12052025_051201.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,666 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 733 | $46.54 | $34,113.82 |
DisclosureSEC source: 0001680329-25-000014 · form4-12052025_051201.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001680329-25-000012 · form4-11252025_051101.xml · derivative · entry 3 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2030-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025 F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10,000 | $79.50 | $795,000.00 |
DisclosureSEC source: 0001680329-25-000012 · form4-11252025_051101.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,666 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025 Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10,000 | $51.16 | $511,600.00 |
DisclosureSEC source: 0001680329-25-000012 · form4-11252025_051101.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025 Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,333 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001680329-25-000010 · form4-11142025_051101.xml · derivative · entry 3 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,467 Underlying: Common Stock · 7,333 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,333 | $74.50 | $546,308.50 |
DisclosureSEC source: 0001680329-25-000010 · form4-11142025_051101.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,666 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,333 | $46.54 | $341,277.82 |
DisclosureSEC source: 0001680329-25-000010 · form4-11142025_051101.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001680329-25-000008 · form4-10312025_051001.xml · derivative · entry 4 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 12,000 | $69.50 | $834,000.00 |
DisclosureSEC source: 0001680329-25-000008 · form4-10312025_051001.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,666 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 12,000 | $38.10 | $457,200.00 |
DisclosureSEC source: 0001680329-25-000008 · form4-10312025_051001.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,666 | $69.50 | $254,787.00 |
DisclosureSEC source: 0001680329-25-000008 · form4-10312025_051001.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,666 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,650 | $0.00 Strike: $33.63 | $0.00 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · derivative · entry 15 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,650 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F11 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,912 | $0.00 Strike: $33.02 | $0.00 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · derivative · entry 14 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,912 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F11 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $33.63 | $0.00 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · derivative · entry 13 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F11 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,884 | $66.89 | $126,020.76 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 12 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,332 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F10 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,037 | $66.10 | $266,845.70 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 11 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,216 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.46 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,729 | $65.05 | $177,521.45 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 10 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,253 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 8,650 | $33.63 | $290,899.50 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 9 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,600 | $66.93 | $107,088.00 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 8 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,332 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,149 | $66.11 | $208,180.39 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 7 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,932 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,163 | $65.02 | $140,638.26 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 6 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,081 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,912 | $33.02 | $228,234.24 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 5 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,381 | $66.87 | $159,217.47 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,332 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.50 to $67.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,591 | $66.09 | $303,419.19 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,713 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,028 | $65.09 | $197,092.52 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,304 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10,000 | $39.42 | $394,200.00 |
DisclosureSEC source: 0001680329-25-000006 · form4-10072025_051012.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 837 | $0.00 Strike: $33.63 | $0.00 |
DisclosureSEC source: 0001680329-25-000004 · form4-09162025_050903.xml · derivative · entry 8 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 837 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001680329-25-000004 · form4-09162025_050903.xml · derivative · entry 7 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2034-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 837 | $59.50 | $49,801.50 |
DisclosureSEC source: 0001680329-25-000004 · form4-09162025_050903.xml · nonDerivative · entry 6 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,332 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 837 | $33.63 | $28,148.31 |
DisclosureSEC source: 0001680329-25-000004 · form4-09162025_050903.xml · nonDerivative · entry 5 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10,000 | $59.50 | $595,000.00 |
DisclosureSEC source: 0001680329-25-000004 · form4-09162025_050903.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,332 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10,000 | $25.69 | $256,900.00 |
DisclosureSEC source: 0001680329-25-000004 · form4-09162025_050903.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,334 | $59.50 | $79,373.00 |
DisclosureSEC source: 0001680329-25-000004 · form4-09162025_050903.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,332 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,534 | $59.50 | $210,273.00 |
DisclosureSEC source: 0001680329-25-000004 · form4-09162025_050903.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,666 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:54 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 40,006 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001415889-25-017410 · form4-06162025_080636.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,006 Underlying: Common Stock · 40,006 shares Expires 2035-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001025 · form4-01072025_050122.xml · derivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2034-02-15 F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001025 · form4-01072025_050122.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,200 F1 · shares: Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:09 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 45,832 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001415889-24-016870 · form4-06142024_080619.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,832 Underlying: Common Stock · 45,832 shares Expires 2034-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2024. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001650664-24-000060 · wk-form4_1717446617.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025 Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004100 · form4-02162024_040209.xml · derivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-02-15 F2 · derivative.exercise_date: This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004100 · form4-02162024_040209.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,200 F1 · shares: Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025. Read SEC document |
| June 15, 2023 Filed Jun 21, 2023 00:19 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 28,255 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001209191-23-038663 · doc4.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,255 Underlying: Common Stock · 28,255 shares Expires 2033-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 15, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.